Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY  - ELEC
LB  - 1.
AU  - Cancer Research UK
TI  - Breast Cancer Statistics
UR  - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer
M1  - 3 July 2020
ER  - 
TY  - JOUR
LB  - 2.
AU  - Slamon, DJ
AU  - Clark, GM
AU  - Wong, SG
AU  - Levin, WJ
AU  - Ullrich, A
AU  - McGuire, WL
TI  - Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
J2  - Science
PY  - 1987
VL  - 235
SP  - 177
EP  - 182
UR  - https://doi.org/10.1126/science.3798106
ER  - 
TY  - JOUR
LB  - 3.
AU  - Perou, CM
AU  - Sørlie, T
AU  - Eisen, MB
AU  - van de Rijn, M
AU  - Jeffrey, SS
AU  - Rees, CA
TI  - Molecular portraits of human breast tumours
J2  - Nature
PY  - 2000
VL  - 406
SP  - 747
EP  - 752
UR  - https://doi.org/10.1038/35021093
ER  - 
TY  - JOUR
LB  - 4.
AU  - Prat, A
AU  - Pineda, E
AU  - Adamo, B
AU  - Galván, P
AU  - Fernández, A
AU  - Gaba, L
TI  - Clinical implications of the intrinsic molecular subtypes of breast cancer
J2  - Breast
PY  - 2015
VL  - 24
IS  - Suppl. 2
SP  - 26
EP  - 35
UR  - https://doi.org/10.1016/j.breast.2015.07.008
ER  - 
TY  - JOUR
LB  - 5.
AU  - Curtis, C
AU  - Shah, SP
AU  - Chin, SF
AU  - Turashvili, G
AU  - Rueda, OM
AU  - Dunning, MJ
TI  - The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
J2  - Nature
PY  - 2012
VL  - 486
SP  - 346
EP  - 352
UR  - https://doi.org/10.1038/nature10983
ER  - 
TY  - JOUR
LB  - 6.
AU  - Slamon, DJ
AU  - Leyland-Jones, B
AU  - Shak, S
AU  - Fuchs, H
AU  - Paton, V
AU  - Bajamonde, A
TI  - Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
J2  - N Engl J Med
PY  - 2001
VL  - 344
SP  - 783
EP  - 792
UR  - https://doi.org/10.1056/NEJM200103153441101
ER  - 
TY  - JOUR
LB  - 7.
AU  - Vogel, CL
AU  - Cobleigh, MA
AU  - Tripathy, D
AU  - Gutheil, JC
AU  - Harris, LN
AU  - Fehrenbacher, L
TI  - Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
J2  - J Clin Oncol
PY  - 2002
VL  - 20
SP  - 719
EP  - 726
UR  - https://doi.org/10.1200/JCO.2002.20.3.719
ER  - 
TY  - JOUR
LB  - 8.
AU  - Moja, L
AU  - Tagliabue, L
AU  - Balduzzi, S
AU  - Parmelli, E
AU  - Pistotti, V
AU  - Guarneri, V
AU  - D’Amico, R
TI  - Trastuzumab containing regimens for early breast cancer
J2  - Cochrane Database Syst Rev
PY  - 2012
VL  - 4
UR  - https://doi.org/10.1002/14651858.CD006243.pub2
ER  - 
TY  - JOUR
LB  - 9.
AU  - Dawson, SJ
AU  - Tsui, DW
AU  - Murtaza, M
AU  - Biggs, H
AU  - Rueda, OM
AU  - Chin, SF
TI  - Analysis of circulating tumor DNA to monitor metastatic breast cancer
J2  - N Engl J Med
PY  - 2013
VL  - 368
SP  - 1199
EP  - 1209
UR  - https://doi.org/10.1056/NEJMoa1213261
ER  - 
TY  - JOUR
LB  - 10.
AU  - Piccart-Gebhart, MJ
AU  - Procter, M
AU  - Leyland-Jones, B
AU  - Goldhirsch, A
AU  - Untch, M
AU  - Smith, I
TI  - Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
J2  - N Engl J Med
PY  - 2005
VL  - 353
SP  - 1659
EP  - 1672
UR  - https://doi.org/10.1056/NEJMoa052306
ER  - 
TY  - JOUR
LB  - 11.
AU  - Smith, I
AU  - Procter, M
AU  - Gelber, RD
AU  - Guillaume, S
AU  - Feyereislova, A
AU  - Dowsett, M
TI  - 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
J2  - Lancet
PY  - 2007
VL  - 369
SP  - 29
EP  - 36
UR  - https://doi.org/10.1016/S0140-6736(07)60028-2
ER  - 
TY  - JOUR
LB  - 12.
AU  - Goldhirsch, A
AU  - Gelber, RD
AU  - Piccart-Gebhart, MJ
AU  - de Azambuja, E
AU  - Procter, M
AU  - Suter, TM
TI  - 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
J2  - Lancet
PY  - 2013
VL  - 382
SP  - 1021
EP  - 1028
UR  - https://doi.org/10.1016/S0140-6736(13)61094-6
ER  - 
TY  - JOUR
LB  - 13.
AU  - Cameron, D
AU  - Piccart-Gebhart, MJ
AU  - Gelber, RD
AU  - Procter, M
AU  - Goldhirsch, A
AU  - de Azambuja, E
TI  - 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
J2  - Lancet
PY  - 2017
VL  - 389
SP  - 1195
EP  - 1205
UR  - https://doi.org/10.1016/S0140-6736(16)32616-2
ER  - 
TY  - JOUR
LB  - 14.
AU  - Joensuu, H
TI  - Duration of adjuvant trastuzumab: shorter beats longer
J2  - Lancet
PY  - 2013
VL  - 382
SP  - 1010
EP  - 1011
UR  - https://doi.org/10.1016/S0140-6736(13)61448-8
ER  - 
TY  - JOUR
LB  - 15.
AU  - Romond, EH
AU  - Perez, EA
AU  - Bryant, J
AU  - Suman, VJ
AU  - Geyer, CE
AU  - Davidson, NE
TI  - Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
J2  - N Engl J Med
PY  - 2005
VL  - 353
SP  - 1673
EP  - 1684
UR  - https://doi.org/10.1056/NEJMoa052122
ER  - 
TY  - JOUR
LB  - 16.
AU  - Perez, EA
AU  - Suman, VJ
AU  - Davidson, NE
AU  - Gralow, JR
AU  - Kaufman, PA
AU  - Visscher, DW
TI  - Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
J2  - J Clin Oncol
PY  - 2011
VL  - 29
SP  - 4491
EP  - 4497
UR  - https://doi.org/10.1200/JCO.2011.36.7045
ER  - 
TY  - JOUR
LB  - 17.
AU  - Perez, EA
AU  - Romond, EH
AU  - Suman, VJ
AU  - Jeong, JH
AU  - Sledge, G
AU  - Geyer, CE
TI  - Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831
J2  - J Clin Oncol
PY  - 2014
VL  - 32
SP  - 3744
EP  - 3752
UR  - https://doi.org/10.1200/JCO.2014.55.5730
ER  - 
TY  - JOUR
LB  - 18.
AU  - Slamon, D
AU  - Eiermann, W
AU  - Robert, N
AU  - Pienkowski, T
AU  - Martin, M
AU  - Press, M
TI  - Adjuvant trastuzumab in HER2-positive breast cancer
J2  - N Engl J Med
PY  - 2011
VL  - 365
SP  - 1273
EP  - 1283
UR  - https://doi.org/10.1056/NEJMoa0910383
ER  - 
TY  - JOUR
LB  - 19.
AU  - Spielmann, M
AU  - Roché, H
AU  - Delozier, T
AU  - Canon, JL
AU  - Romieu, G
AU  - Bourgeois, H
TI  - Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial
J2  - J Clin Oncol
PY  - 2009
VL  - 27
SP  - 6129
EP  - 6134
UR  - https://doi.org/10.1200/JCO.2009.23.0946
ER  - 
TY  - JOUR
LB  - 20.
AU  - Joensuu, H
AU  - Kellokumpu-Lehtinen, PL
AU  - Bono, P
AU  - Alanko, T
AU  - Kataja, V
AU  - Asola, R
TI  - Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
J2  - N Engl J Med
PY  - 2006
VL  - 354
SP  - 809
EP  - 820
UR  - https://doi.org/10.1056/NEJMoa053028
ER  - 
TY  - JOUR
LB  - 21.
AU  - Joensuu, H
AU  - Bono, P
AU  - Kataja, V
AU  - Alanko, T
AU  - Kokko, R
AU  - Asola, R
TI  - Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial
J2  - J Clin Oncol
PY  - 2009
VL  - 27
SP  - 5685
EP  - 5692
UR  - https://doi.org/10.1200/JCO.2008.21.4577
ER  - 
TY  - JOUR
LB  - 22.
AU  - Schneider, BP
AU  - O’Neill, A
AU  - Shen, F
AU  - Sledge, GW
AU  - Thor, AD
AU  - Kahanic, SP
TI  - Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)
J2  - Br J Cancer
PY  - 2015
VL  - 113
SP  - 1651
EP  - 1657
UR  - https://doi.org/10.1038/bjc.2015.405
ER  - 
TY  - JOUR
LB  - 23.
AU  - Pivot, X
AU  - Romieu, G
AU  - Debled, M
AU  - Pierga, JY
AU  - Kerbrat, P
AU  - Bachelot, T
TI  - 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
J2  - Lancet Oncol
PY  - 2013
VL  - 14
SP  - 741
EP  - 748
UR  - https://doi.org/10.1016/S1470-2045(13)70225-0
ER  - 
TY  - JOUR
LB  - 24.
AU  - Mavroudis, D
AU  - Saloustros, E
AU  - Malamos, N
AU  - Kakolyris, S
AU  - Boukovinas, I
AU  - Papakotoulas, P
TI  - Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
J2  - Ann Oncol
PY  - 2015
VL  - 26
SP  - 1333
EP  - 1340
UR  - https://doi.org/10.1093/annonc/mdv213
ER  - 
TY  - JOUR
LB  - 25.
AU  - Joensuu, H
AU  - Fraser, J
AU  - Wildiers, H
AU  - Huovinen, R
AU  - Auvinen, P
AU  - Utriainen, M
TI  - Effect of adjuvant trastuzumab for a duration of 9 weeks vs. 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial
J2  - JAMA Oncol
PY  - 2018
VL  - 4
SP  - 1199
EP  - 1206
UR  - https://doi.org/10.1001/jamaoncol.2018.1380
ER  - 
TY  - JOUR
LB  - 26.
AU  - Conte, P
AU  - Frassoldati, A
AU  - Bisagni, G
AU  - Brandes, AA
AU  - Donadio, M
AU  - Garrone, O
TI  - Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
J2  - Ann Oncol
PY  - 2018
VL  - 29
SP  - 2328
EP  - 2333
UR  - https://doi.org/10.1093/annonc/mdy414
ER  - 
TY  - ELEC
LB  - 27.
AU  - International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
TI  - Efficacy Guidelines
UR  - www.ich.org/page/efficacy-guidelines
M1  - 3 July 2020
ER  - 
TY  - ELEC
LB  - 28.
AU  - NHS Health Research Authority
TI  - Good Clinical Practice
UR  - www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/good-clinical-practice/
M1  - 3 July 2020
ER  - 
TY  - GEN
LB  - 29.
AU  - Great Britain
TI  - The Medicines for Human Use (Clinical Trials) Regulations 2004
CY  - London
PB  - The Stationery Office
PY  - 2004
ER  - 
TY  - ELEC
LB  - 30.
AU  - NHS Health Research Authority
TI  - Clinical Trials of Investigational Medicinal Products (CTIMPS)
UR  - www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/clinical-trials-investigational-medicinal-products-ctimps/
M1  - 3 July 2020
ER  - 
TY  - ELEC
LB  - 31.
AU  - Warwick Clinical Trials Unit
TI  - Persephone Protocol v5.0 Sept 2019
UR  - https://warwick.ac.uk/fac/sci/med/research/ctu/trials/cancer/persephone/professionals
M1  - 3 July 2020
ER  - 
TY  - JOUR
LB  - 32.
AU  - Ellis, IO
AU  - Bartlett, J
AU  - Dowsett, M
AU  - Humphreys, S
AU  - Jasani, B
AU  - Miller, K
TI  - Best Practice No. 176: updated recommendations for HER2 testing in the UK
J2  - J Clin Pathol
PY  - 2004
VL  - 57
SP  - 233
EP  - 237
UR  - https://doi.org/10.1136/jcp.2003.007724
ER  - 
TY  - JOUR
LB  - 33.
AU  - Walker, RA
AU  - Bartlett, JM
AU  - Dowsett, M
AU  - Ellis, IO
AU  - Hanby, AM
AU  - Jasani, B
TI  - HER2 testing in the UK: further update to recommendations
J2  - J Clin Pathol
PY  - 2008
VL  - 61
SP  - 818
EP  - 824
UR  - https://doi.org/10.1136/jcp.2007.054866
ER  - 
TY  - JOUR
LB  - 34.
AU  - Rakha, EA
AU  - Pinder, SE
AU  - Bartlett, JM
AU  - Ibrahim, M
AU  - Starczynski, J
AU  - Carder, PJ
TI  - Updated UK recommendations for HER2 assessment in breast cancer
J2  - J Clin Pathol
PY  - 2015
VL  - 68
SP  - 93
EP  - 99
UR  - https://doi.org/10.1136/jclinpath-2014-202571
ER  - 
TY  - JOUR
LB  - 35.
AU  - Press, MF
AU  - Sauter, G
AU  - Buyse, M
AU  - Fourmanoir, H
AU  - Quinaux, E
AU  - Tsao-Wei, DD
TI  - HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in Breast Cancer International Research Group Clinical Trials
J2  - J Clin Oncol
PY  - 2016
VL  - 34
SP  - 3518
EP  - 3528
UR  - https://doi.org/10.1200/JCO.2016.66.6693
ER  - 
TY  - JOUR
LB  - 36.
AU  - Jones, AL
AU  - Barlow, M
AU  - Barrett-Lee, PJ
AU  - Canney, PA
AU  - Gilmour, IM
AU  - Robb, SD
TI  - Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
J2  - Br J Cancer
PY  - 2009
VL  - 100
SP  - 684
EP  - 692
UR  - https://doi.org/10.1038/sj.bjc.6604909
ER  - 
TY  - ELEC
LB  - 37.
AU  - Cancer Research UK
TI  - Trans-PERSEPHONE and Trans-PERSEPHONE-SNPs: The Pharmacogenomics and Pharmacogenetics of Adjuvant Trastuzumab. Cancer Research Translational research in Clinical Trials Committee Project Grant: Funding Reference Number: C507/A9675, 2008–2015
UR  - https://europepmc.org/grantfinder/grantdetails?query=pi%3A%22Caldas%2BC%22%2Bgid%3A%22A18832%22%2Bga%3A%22Cancer%20Research%20UK%22
ER  - 
TY  - JOUR
LB  - 38.
AU  - Ismael, G
AU  - Hegg, R
AU  - Muehlbauer, S
AU  - Heinzmann, D
AU  - Lum, B
AU  - Kim, SB
TI  - Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
J2  - Lancet Oncol
PY  - 2012
VL  - 13
SP  - 869
EP  - 878
UR  - https://doi.org/10.1016/S1470-2045(12)70329-7
ER  - 
TY  - JOUR
LB  - 39.
AU  - Mauri, L
AU  - D’Agostino, RB
TI  - Challenges in the design and interpretation of noninferiority trials
J2  - N Engl J Med
PY  - 2017
VL  - 377
SP  - 1357
EP  - 1367
UR  - https://doi.org/10.1056/NEJMra1510063
ER  - 
TY  - JOUR
LB  - 40.
AU  - Grothey, A
AU  - Sobrero, AF
AU  - Shields, AF
AU  - Yoshino, T
AU  - Paul, J
AU  - Taieb, J
TI  - Duration of adjuvant chemotherapy for stage III colon cancer
J2  - N Engl J Med
PY  - 2018
VL  - 378
SP  - 1177
EP  - 1188
UR  - https://doi.org/10.1056/NEJMoa1713709
ER  - 
TY  - JOUR
LB  - 41.
AU  - Mehanna, H
AU  - Wong, WL
AU  - McConkey, CC
AU  - Rahman, JK
AU  - Robinson, M
AU  - Hartley, AG
TI  - PET-CT surveillance versus neck dissection in advanced head and neck cancer
J2  - N Engl J Med
PY  - 2016
VL  - 374
SP  - 1444
EP  - 1454
UR  - https://doi.org/10.1056/NEJMoa1514493
ER  - 
TY  - JOUR
LB  - 42.
AU  - Sparano, JA
AU  - Gray, RJ
AU  - Makower, DF
AU  - Pritchard, KI
AU  - Albain, KS
AU  - Hayes, DF
TI  - Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer
J2  - N Engl J Med
PY  - 2018
VL  - 379
SP  - 111
EP  - 121
UR  - https://doi.org/10.1056/NEJMoa1804710
ER  - 
TY  - JOUR
LB  - 43.
AU  - Moher, D
AU  - Schulz, KF
AU  - Altman, DG
TI  - The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
J2  - Lancet
PY  - 2001
VL  - 357
SP  - 1191
EP  - 1194
UR  - https://doi.org/10.1016/S0140-6736(00)04337-3
ER  - 
TY  - GEN
LB  - 44.
AU  - Early Breast Cancer Trialists’ Collaborative Group
TI  - Treatment of Early Breast Cancer: Worldwide Evidence 1985–1990
CY  - Oxford
PB  - Oxford University Press
PY  - 1990
ER  - 
TY  - BOOK
LB  - 45.
AU  - Jennison, C
AU  - Turnbull, BW
TI  - Group Sequential Methods with Applications to Clinical Trials
CY  - Boca Raton, FL
PB  - Chapman and Hall/CRC
PY  - 1999
UR  - https://doi.org/10.1201/9781584888581
ER  - 
TY  - JOUR
LB  - 46.
AU  - Freidlin, B
AU  - Korn, EL
AU  - Gray, R
TI  - A general inefficacy interim monitoring rule for randomized clinical trials
J2  - Clin Trials
PY  - 2010
VL  - 7
SP  - 197
EP  - 208
UR  - https://doi.org/10.1177/1740774510369019
ER  - 
TY  - JOUR
LB  - 47.
AU  - Pivot, X
AU  - Romieu, G
AU  - Bonnefoi, H
AU  - Pierga, JY
AU  - Kerbrat, P
AU  - Guastalla, JP
TI  - PHARE trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer
J2  - Ann Oncol
PY  - 2012
VL  - 23
IS  - Suppl. 9
SP  - ixe1
EP  - ixe30
UR  - https://doi.org/10.1016/S0923-7534(20)34322-2
ER  - 
TY  - JOUR
LB  - 48.
AU  - Goldhirsch, A
AU  - Piccartt, MJ
AU  - Procter, M
AU  - de Azambuja, E
AU  - Weber, HA
AU  - Untch, M
TI  - HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up
J2  - Ann Oncol
PY  - 2012
VL  - 23
IS  - Suppl. 9
SP  - ixe1
EP  - ixe30
UR  - https://doi.org/10.1016/S0923-7534(20)34333-7
ER  - 
TY  - ELEC
LB  - 49.
AU  - Independent Cancer Patients’ Voice
TI  - About Us
UR  - www.independentcancerpatientsvoice.org.uk/about-us/
ER  - 
TY  - JOUR
LB  - 50.
AU  - DerSimonian, R
AU  - Laird, N
TI  - Meta-analysis in clinical trials
J2  - Control Clin Trials
PY  - 1986
VL  - 7
SP  - 177
EP  - 188
UR  - https://doi.org/10.1016/0197-2456(86)90046-2
ER  - 
TY  - JOUR
LB  - 51.
AU  - Pivot, X
AU  - Romieu, G
AU  - Debled, M
AU  - Pierga, JY
AU  - Kerbrat, P
AU  - Bachelot, T
TI  - 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
J2  - Lancet
PY  - 2019
VL  - 393
SP  - 2591
EP  - 2598
ER  - 
TY  - JOUR
LB  - 52.
AU  - Seidman, A
AU  - Hudis, C
AU  - Pierri, MK
AU  - Shak, S
AU  - Paton, V
AU  - Ashby, M
TI  - Cardiac dysfunction in the trastuzumab clinical trials experience
J2  - J Clin Oncol
PY  - 2002
VL  - 20
SP  - 1215
EP  - 1221
UR  - https://doi.org/10.1200/JCO.2002.20.5.1215
ER  - 
TY  - JOUR
LB  - 53.
AU  - Tan-Chiu, E
AU  - Yothers, G
AU  - Romond, E
AU  - Geyer, CE
AU  - Ewer, M
AU  - Keefe, D
TI  - Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
J2  - J Clin Oncol
PY  - 2005
VL  - 23
SP  - 7811
EP  - 7819
UR  - https://doi.org/10.1200/JCO.2005.02.4091
ER  - 
TY  - JOUR
LB  - 54.
AU  - Suter, TM
AU  - Procter, M
AU  - van Veldhuisen, DJ
AU  - Muscholl, M
AU  - Bergh, J
AU  - Carlomagno, C
TI  - Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
J2  - J Clin Oncol
PY  - 2007
VL  - 25
SP  - 3859
EP  - 3865
UR  - https://doi.org/10.1200/JCO.2006.09.1611
ER  - 
TY  - JOUR
LB  - 55.
AU  - Procter, M
AU  - Suter, TM
AU  - de Azambuja, E
AU  - Dafni, U
AU  - van Dooren, V
AU  - Muehlbauer, S
TI  - Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial
J2  - J Clin Oncol
PY  - 2010
VL  - 28
SP  - 3422
EP  - 3428
UR  - https://doi.org/10.1200/JCO.2009.26.0463
ER  - 
TY  - JOUR
LB  - 56.
AU  - de Azambuja, E
AU  - Procter, MJ
AU  - van Veldhuisen, DJ
AU  - Agbor-Tarh, D
AU  - Metzger-Filho, O
AU  - Steinseifer, J
TI  - Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)
J2  - J Clin Oncol
PY  - 2014
VL  - 32
SP  - 2159
EP  - 2165
UR  - https://doi.org/10.1200/JCO.2013.53.9288
ER  - 
TY  - JOUR
LB  - 57.
AU  - Perez, EA
AU  - Suman, VJ
AU  - Davidson, NE
AU  - Sledge, GW
AU  - Kaufman, PA
AU  - Hudis, CA
TI  - Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
J2  - J Clin Oncol
PY  - 2008
VL  - 26
SP  - 1231
EP  - 1238
UR  - https://doi.org/10.1200/JCO.2007.13.5467
ER  - 
TY  - JOUR
LB  - 58.
AU  - Russell, SD
AU  - Blackwell, KL
AU  - Lawrence, J
AU  - Pippen, JE
AU  - Roe, MT
AU  - Wood, F
TI  - Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials
J2  - J Clin Oncol
PY  - 2010
VL  - 28
SP  - 3416
EP  - 3421
UR  - https://doi.org/10.1200/JCO.2009.23.6950
ER  - 
TY  - JOUR
LB  - 59.
AU  - Zeglinski, M
AU  - Ludke, A
AU  - Jassal, DS
AU  - Singal, PK
TI  - Trastuzumab-induced cardiac dysfunction: a ‘dual-hit’
J2  - Exp Clin Cardiol
PY  - 2011
VL  - 16
SP  - 70
EP  - 74
ER  - 
TY  - JOUR
LB  - 60.
AU  - Force, T
AU  - Krause, DS
AU  - Van Etten, RA
TI  - Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
J2  - Nat Rev Cancer
PY  - 2007
VL  - 7
SP  - 332
EP  - 344
UR  - https://doi.org/10.1038/nrc2106
ER  - 
TY  - JOUR
LB  - 61.
AU  - Ewer, MS
AU  - Gibbs, HR
AU  - Swafford, J
AU  - Benjamin, RS
TI  - Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?
J2  - Semin Oncol
PY  - 1999
VL  - 26
IS  - Suppl. 4
SP  - 96
EP  - 101
ER  - 
TY  - JOUR
LB  - 62.
AU  - Ewer, MS
AU  - Vooletich, MT
AU  - Durand, JB
AU  - Woods, ML
AU  - Davis, JR
AU  - Valero, V
AU  - Lenihan, DJ
TI  - Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment
J2  - J Clin Oncol
PY  - 2005
VL  - 23
SP  - 7820
EP  - 7826
UR  - https://doi.org/10.1200/JCO.2005.13.300
ER  - 
TY  - JOUR
LB  - 63.
AU  - Pivot, X
AU  - Suter, T
AU  - Nabholtz, JM
AU  - Pierga, JY
AU  - Espie, M
AU  - Lortholary, A
TI  - Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study
J2  - Eur J Cancer
PY  - 2015
VL  - 51
SP  - 1660
EP  - 1666
UR  - https://doi.org/10.1016/j.ejca.2015.05.028
ER  - 
TY  - JOUR
LB  - 64.
AU  - Mantarro, S
AU  - Rossi, M
AU  - Bonifazi, M
AU  - D’Amico, R
AU  - Blandizzi, C
AU  - La Vecchia, C
TI  - Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer
J2  - Intern Emerg Med
PY  - 2016
VL  - 11
SP  - 123
EP  - 140
UR  - https://doi.org/10.1007/s11739-015-1362-x
ER  - 
TY  - EDBOOK
LB  - 65.
AU  - Dolgin, M
AU  - Fox, AC
AU  - Levin, RI
TI  - Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels
CY  - London
PB  - Little, Brown
PY  - 1994
ER  - 
TY  - JOUR
LB  - 66.
AU  - Raphael, C
AU  - Briscoe, C
AU  - Davies, J
AU  - Whinnett, ZI
AU  - Manisty, C
AU  - Sutton, R
TI  - Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure
J2  - Heart
PY  - 2007
VL  - 93
SP  - 476
EP  - 482
UR  - https://doi.org/10.1136/hrt.2006.089656
ER  - 
TY  - JOUR
LB  - 67.
AU  - Beauclair, S
AU  - Formento, P
AU  - Fischel, JL
AU  - Lescaut, W
AU  - Largillier, R
AU  - Chamorey, E
TI  - Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
J2  - Ann Oncol
PY  - 2007
VL  - 18
SP  - 1335
EP  - 1341
UR  - https://doi.org/10.1093/annonc/mdm181
ER  - 
TY  - JOUR
LB  - 68.
AU  - Ng, T
AU  - Chan, M
AU  - Khor, CC
AU  - Ho, HK
AU  - Chan, A
TI  - The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review
J2  - Cancer Treat Rev
PY  - 2014
VL  - 40
SP  - 1199
EP  - 1214
UR  - https://doi.org/10.1016/j.ctrv.2014.10.001
ER  - 
TY  - JOUR
LB  - 69.
AU  - Halyard, MY
AU  - Pisansky, TM
AU  - Dueck, AC
AU  - Suman, V
AU  - Pierce, L
AU  - Solin, L
TI  - Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831
J2  - J Clin Oncol
PY  - 2009
VL  - 27
SP  - 2638
EP  - 2644
UR  - https://doi.org/10.1200/JCO.2008.17.9549
ER  - 
TY  - JOUR
LB  - 70.
AU  - Leong, SL
AU  - Chaiyakunapruk, N
AU  - Tassaneeyakul, W
AU  - Arunmanakul, P
AU  - Nathisuwan, S
AU  - Lee, SWH
TI  - Roles of pharmacogenomics in non-anthracycline antineoplastic-induced cardiovascular toxicities: a systematic review and meta-analysis of genotypes effect
J2  - Int J Cardiol
PY  - 2019
VL  - 280
SP  - 190
EP  - 197
UR  - https://doi.org/10.1016/j.ijcard.2018.12.049
ER  - 
TY  - JOUR
LB  - 71.
AU  - Roca, L
AU  - Diéras, V
AU  - Roché, H
AU  - Lappartient, E
AU  - Kerbrat, P
AU  - Cany, L
TI  - Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial
J2  - Breast Cancer Res Treat
PY  - 2013
VL  - 139
SP  - 789
EP  - 800
UR  - https://doi.org/10.1007/s10549-013-2587-x
ER  - 
TY  - JOUR
LB  - 72.
AU  - Darby, SC
AU  - Ewertz, M
AU  - McGale, P
AU  - Bennet, AM
AU  - Blom-Goldman, U
AU  - Brønnum, D
TI  - Risk of ischemic heart disease in women after radiotherapy for breast cancer
J2  - N Engl J Med
PY  - 2013
VL  - 368
SP  - 987
EP  - 998
UR  - https://doi.org/10.1056/NEJMoa1209825
ER  - 
TY  - JOUR
LB  - 73.
AU  - Earl, H
AU  - Hiller, L
AU  - Dunn, J
AU  - Blenkinsop, C
AU  - Grybowicz, L
AU  - Vallier, AL
TI  - Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: the ARTemis trial
J2  - J Clin Oncol
PY  - 2016
VL  - 34
IS  - Suppl.
SP  - 1014
UR  - https://doi.org/10.1200/JCO.2016.34.15_suppl.1014
ER  - 
TY  - JOUR
LB  - 74.
AU  - Poole, CJ
AU  - Earl, HM
AU  - Hiller, L
AU  - Dunn, JA
AU  - Bathers, S
AU  - Grieve, RJ
TI  - Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer
J2  - N Engl J Med
PY  - 2006
VL  - 355
SP  - 1851
EP  - 1862
UR  - https://doi.org/10.1056/NEJMoa052084
ER  - 
TY  - JOUR
LB  - 75.
AU  - Early Breast Cancer Trialists’ Collaborative Group
TI  - Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
J2  - Lancet
PY  - 2005
VL  - 365
SP  - 1687
EP  - 1717
UR  - https://doi.org/10.1016/S0140-6736(05)66544-0
ER  - 
TY  - JOUR
LB  - 76.
AU  - Bartlett, JM
AU  - McConkey, CC
AU  - Munro, AF
AU  - Desmedt, C
AU  - Dunn, JA
AU  - Larsimont, DP
TI  - Predicting anthracycline benefit: TOP2A and CEP17-not only but also
J2  - J Clin Oncol
PY  - 2015
VL  - 33
SP  - 1680
EP  - 1687
UR  - https://doi.org/10.1200/JCO.2013.54.7869
ER  - 
TY  - JOUR
LB  - 77.
AU  - Brooks, R
TI  - EuroQol: the current state of play
J2  - Health Policy
PY  - 1996
VL  - 37
SP  - 53
EP  - 72
UR  - https://doi.org/10.1016/0168-8510(96)00822-6
ER  - 
TY  - GEN
LB  - 78.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Guide to the Methods of Technology Appraisal 2013
CY  - London
PB  - NICE
PY  - 2013
UR  - www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781
Y2  - 3 July 2020
ER  - 
TY  - JOUR
LB  - 79.
AU  - Dolan, P
TI  - Modeling valuations for EuroQol health states
J2  - Med Care
PY  - 1997
VL  - 35
SP  - 1095
EP  - 1108
UR  - https://doi.org/10.1097/00005650-199711000-00002
ER  - 
TY  - BOOK
LB  - 80.
AU  - Dolan, P
AU  - Gudex, C
AU  - Kind, P
AU  - Williams, A
TI  - A Social Tariff for EuroQol: Results From a UK General Population Survey
CY  - York
PB  - Centre for Health Economics, University of York
PY  - 1995
ER  - 
TY  - JOUR
LB  - 81.
AU  - Shen, LZ
AU  - Pulkstenis, E
AU  - Hoseyni, M
TI  - Estimation of mean quality adjusted survival time
J2  - Stat Med
PY  - 1999
VL  - 18
SP  - 1541
EP  - 1554
UR  - https://doi.org/10.1002/(SICI)1097-0258(19990630)18:12<1541::AID-SIM139>3.0.CO;2-Z
ER  - 
TY  - JOUR
LB  - 82.
AU  - Matthews, JN
AU  - Altman, DG
AU  - Campbell, MJ
AU  - Royston, P
TI  - Analysis of serial measurements in medical research
J2  - BMJ
PY  - 1990
VL  - 300
SP  - 230
EP  - 235
UR  - https://doi.org/10.1136/bmj.300.6719.230
ER  - 
TY  - JOUR
LB  - 83.
AU  - Lidgren, M
AU  - Wilking, N
AU  - Jonsson, B
AU  - Rehnberg, C
TI  - Health related quality of life in different states of breast cancer
J2  - Qual Life Res
PY  - 2007
VL  - 16
SP  - 1073
EP  - 1081
UR  - https://doi.org/10.1007/s11136-007-9202-8
ER  - 
TY  - JOUR
LB  - 84.
AU  - Hunter, RM
AU  - Baio, G
AU  - Butt, T
AU  - Morris, S
AU  - Round, J
AU  - Freemantle, N
TI  - An educational review of the statistical issues in analysing utility data for cost-utility analysis
J2  - PharmacoEconomics
PY  - 2015
VL  - 33
SP  - 355
EP  - 366
UR  - https://doi.org/10.1007/s40273-014-0247-6
ER  - 
TY  - JOUR
LB  - 85.
AU  - Manca, A
AU  - Hawkins, N
AU  - Sculpher, MJ
TI  - Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility
J2  - Health Econ
PY  - 2005
VL  - 14
SP  - 487
EP  - 496
UR  - https://doi.org/10.1002/hec.944
ER  - 
TY  - BOOK
LB  - 86.
AU  - Curtis, L
AU  - Burns, A
TI  - Unit Costs of Health and Social Care 2018
CY  - Canterbury
PB  - Personal Social Services Research Unit, University of Kent
PY  - 2018
ER  - 
TY  - ELEC
LB  - 87.
AU  - NHS Improvement
TI  - NHS Reference Costs 2017/18
UR  - https://improvement.nhs.uk/resources/reference-costs/
M1  - 3 July 2020
ER  - 
TY  - ELEC
LB  - 88.
AU  - Joint Formulary Committee
TI  - British National Formulary
CY  - London
PB  - BMJ Group and Pharmaceutical Press
PY  - 2018
UR  - www.medicinescomplete.com
M1  - 7 July 2020
ER  - 
TY  - JOUR
LB  - 89.
AU  - O’Brien, GL
AU  - O’Mahony, C
AU  - Cooke, K
AU  - Kinneally, A
AU  - Sinnott, SJ
AU  - Walshe, V
TI  - Cost minimization analysis of intravenous or subcutaneous trastuzumab treatment in patients with HER2-positive breast cancer in Ireland
J2  - Clin Breast Cancer
PY  - 2019
VL  - 19
SP  - e440
EP  - e451
UR  - https://doi.org/10.1016/j.clbc.2019.01.011
ER  - 
TY  - JOUR
LB  - 90.
AU  - Faria, R
AU  - Gomes, M
AU  - Epstein, D
AU  - White, IR
TI  - A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials
J2  - PharmacoEconomics
PY  - 2014
VL  - 32
SP  - 1157
EP  - 1170
UR  - https://doi.org/10.1007/s40273-014-0193-3
ER  - 
TY  - JOUR
LB  - 91.
AU  - Hall, PS
AU  - Hulme, C
AU  - McCabe, C
AU  - Oluboyede, Y
AU  - Round, J
AU  - Cameron, DA
TI  - Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence
J2  - PharmacoEconomics
PY  - 2011
VL  - 29
SP  - 415
EP  - 432
UR  - https://doi.org/10.2165/11588340-000000000-00000
ER  - 
TY  - JOUR
LB  - 92.
AU  - Karnon, J
AU  - Kerr, GR
AU  - Jack, W
AU  - Papo, NL
AU  - Cameron, DA
TI  - Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis
J2  - Br J Cancer
PY  - 2007
VL  - 97
SP  - 479
EP  - 485
UR  - https://doi.org/10.1038/sj.bjc.6603887
ER  - 
TY  - JOUR
LB  - 93.
AU  - Mohan, N
AU  - Jiang, J
AU  - Dokmanovic, M
AU  - Wu, WJ
TI  - Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers
J2  - Antib Ther
PY  - 2018
VL  - 1
SP  - 13
EP  - 17
UR  - https://doi.org/10.1093/abt/tby003
ER  - 
TY  - BOOK
LB  - 94.
AU  - Townsend, N
AU  - Wickramasinghe, K
AU  - Bhatnagar, P
AU  - Smolina, K
AU  - Nichols, M
AU  - Leal, J
TI  - Coronary Heart Disease Statistics 2012 Edition
CY  - London
PB  - British Heart Foundation
PY  - 2012
ER  - 
TY  - ELEC
LB  - 95.
AU  - Office for National Statistics
TI  - National Life Tables: UK
UR  - www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables
M1  - 1 November 2019
ER  - 
TY  - ELEC
LB  - 96.
AU  - Cancer Research UK
TI  - Breast Cancer Mortality Statistics
UR  - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/mortality?_ga=2.233072414.1882256152.1588694623-1974509419.1582545276#heading-One
M1  - 1 November 2019
ER  - 
TY  - JOUR
LB  - 97.
AU  - Jackson, CH
TI  - Multi-state models for panel data: the msm package for R
J2  - Stat Software
PY  - 2011
VL  - 38
SP  - 1
EP  - 29
UR  - https://doi.org/10.18637/jss.v038.i08
ER  - 
TY  - JOUR
LB  - 98.
AU  - Seferina, SC
AU  - Ramaekers, BLT
AU  - de Boer, M
AU  - Dercksen, MW
AU  - van den Berkmortel, F
AU  - van Kampen, RJW
TI  - Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: a study of the Southeast Netherlands Breast Cancer Consortium
J2  - Oncotarget
PY  - 2017
VL  - 8
SP  - 79223
EP  - 79233
UR  - https://doi.org/10.18632/oncotarget.16985
ER  - 
TY  - ELEC
LB  - 99.
AU  - Bank of England
TI  - Inflation Calculator
UR  - www.bankofengland.co.uk/monetary-policy/inflation/inflation-calculator
M1  - 3 July 2020
ER  - 
TY  - GEN
LB  - 100.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Early and Locally Advanced Breast Cancer: Diagnosis and Management
CY  - London
PB  - NICE
PY  - 2018
UR  - www.nice.org.uk/guidance/ng101
Y2  - 3 July 2020
ER  - 
TY  - JOUR
LB  - 101.
AU  - Robertson, C
AU  - Arcot Ragupathy, SK
AU  - Boachie, C
AU  - Dixon, JM
AU  - Fraser, C
AU  - Hernández, R
TI  - The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation
J2  - Health Technol Assess
PY  - 2011
VL  - 15
IS  - 34
UR  - https://doi.org/10.3310/hta15340
ER  - 
TY  - JOUR
LB  - 102.
AU  - Stein, RC
AU  - Dunn, JA
AU  - Bartlett, JM
AU  - Campbell, AF
AU  - Marshall, A
AU  - Hall, P
TI  - OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
J2  - Health Technol Assess
PY  - 2016
VL  - 20
IS  - 10
UR  - https://doi.org/10.3310/hta20100
ER  - 
TY  - JOUR
LB  - 103.
AU  - Hall, P
AU  - Walkington, L
AU  - Newsham, A
AU  - Hall, G
AU  - Glaser, A
TI  - Costs of hospital care over ten years from diagnosis of early breast cancer in England
J2  - Eur J Cancer
PY  - 2014
VL  - 50
SP  - S79
EP  - S80
ER  - 
TY  - GEN
LB  - 104.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Abemaciclib with an Aromatase Inhibitor for Previously Untreated, Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
CY  - London
PB  - NICE
PY  - 2019
UR  - www.nice.org.uk/guidance/ta563
Y2  - 3 July 2020
ER  - 
TY  - GEN
LB  - 105.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Advanced Breast Cancer: Diagnosis and Treatment
CY  - London
PB  - NICE
PY  - 2017
UR  - www.nice.org.uk/guidance/cg81
Y2  - 3 July 2020
ER  - 
TY  - JOUR
LB  - 106.
AU  - Karlsson, G
AU  - Johannesson, M
TI  - The decision rules of cost-effectiveness analysis
J2  - PharmacoEconomics
PY  - 1996
VL  - 9
SP  - 113
EP  - 120
UR  - https://doi.org/10.2165/00019053-199609020-00003
ER  - 
TY  - JOUR
LB  - 107.
AU  - Clarke, CS
AU  - Hunter, RM
AU  - Shemilt, I
AU  - Serra-Sastre, V
TI  - Multi-arm cost-effectiveness analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective
J2  - PLOS ONE
PY  - 2017
VL  - 12
SP  - e0172731
UR  - https://doi.org/10.1371/journal.pone.0172731
ER  - 
TY  - GEN
LB  - 108.
AU  - Cancer Research UK
TI  - Fatigue and Cancer Drugs
CY  - London
PB  - Cancer Research UK
PY  - 2017
UR  - www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/side-effects/fatigue
Y2  - 7 September 2017
ER  - 
TY  - JOUR
LB  - 109.
AU  - Narayanan, V
AU  - Koshy, C
TI  - Fatigue in cancer: a review of literature
J2  - Indian J Palliat Care
PY  - 2009
VL  - 15
SP  - 19
EP  - 25
UR  - https://doi.org/10.4103/0973-1075.53507
ER  - 
TY  - JOUR
LB  - 110.
AU  - Murphy, E
AU  - Dingwall, R
AU  - Greatbatch, D
AU  - Parker, S
AU  - Watson, P
TI  - Qualitative research methods in health technology assessment: a review of the literature
J2  - Health Technol Assess
PY  - 1998
VL  - 2
IS  - 16
UR  - https://doi.org/10.3310/hta2160
ER  - 
TY  - JOUR
LB  - 111.
AU  - Rich, JL
AU  - Chojenta, C
AU  - Loxton, D
TI  - Quality, rigour and usefulness of free-text comments collected by a large population based longitudinal study – ALSWH
J2  - PLOS ONE
PY  - 2013
VL  - 8
SP  - e68832
UR  - https://doi.org/10.1371/journal.pone.0068832
ER  - 
TY  - JOUR
LB  - 112.
AU  - York, GS
AU  - Churchman, R
AU  - Woodard, B
AU  - Wainright, C
AU  - Rau-Foster, M
TI  - Free-text comments: understanding the value in family member descriptions of hospice caregiver relationships
J2  - Am J Hosp Palliat Care
PY  - 2012
VL  - 29
SP  - 98
EP  - 105
UR  - https://doi.org/10.1177/1049909111409564
ER  - 
TY  - JOUR
LB  - 113.
AU  - Corner, J
AU  - Wagland, R
AU  - Glaser, A
AU  - Richards, SM
TI  - Qualitative analysis of patients’ feedback from a PROMs survey of cancer patients in England
J2  - BMJ Open
PY  - 2013
VL  - 3
SP  - e002316
UR  - https://doi.org/10.1136/bmjopen-2012-002316
ER  - 
TY  - JOUR
LB  - 114.
AU  - Parsonage, RK
AU  - Hiscock, J
AU  - Law, RJ
AU  - Neal, RD
TI  - Patient perspectives on delays in diagnosis and treatment of cancer: a qualitative analysis of free-text data
J2  - Br J Gen Pract
PY  - 2017
VL  - 67
SP  - e49
EP  - e56
UR  - https://doi.org/10.3399/bjgp16X688357
ER  - 
TY  - JOUR
LB  - 115.
AU  - O’Cathain, A
AU  - Thomas, KJ
TI  - ‘Any other comments?’ Open questions on questionnaires – a bane or a bonus to research?
J2  - BMC Med Res Methodol
PY  - 2004
VL  - 4
SP  - 25
UR  - https://doi.org/10.1186/1471-2288-4-25
ER  - 
TY  - JOUR
LB  - 116.
AU  - Hortobagyi, GN
TI  - Trastuzumab in the treatment of breast cancer
J2  - N Engl J Med
PY  - 2005
VL  - 353
SP  - 1734
EP  - 1736
UR  - https://doi.org/10.1056/NEJMe058196
ER  - 
TY  - JOUR
LB  - 117.
AU  - Piaggio, G
AU  - Elbourne, DR
AU  - Pocock, SJ
AU  - Evans, SJ
AU  - Altman, DG
AU  - CONSORT Group
TI  - Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement
J2  - JAMA
PY  - 2012
VL  - 308
SP  - 2594
EP  - 2604
UR  - https://doi.org/10.1001/jama.2012.87802
ER  - 
TY  - JOUR
LB  - 118.
AU  - Hudis, CA
AU  - Barlow, WE
AU  - Costantino, JP
AU  - Gray, RJ
AU  - Pritchard, KI
AU  - Chapman, JA
TI  - Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system
J2  - J Clin Oncol
PY  - 2007
VL  - 25
SP  - 2127
EP  - 2132
UR  - https://doi.org/10.1200/JCO.2006.10.3523
ER  - 
TY  - JOUR
LB  - 119.
AU  - DerSimonian, R
AU  - Laird, N
TI  - Meta-analysis in clinical trials revisited
J2  - Contemp Clin Trials
PY  - 2015
VL  - 45
IS  - Pt A
SP  - 139
EP  - 145
UR  - https://doi.org/10.1016/j.cct.2015.09.002
ER  - 
TY  - JOUR
LB  - 120.
AU  - Tolaney, SM
AU  - Barry, WT
AU  - Dang, CT
AU  - Yardley, DA
AU  - Moy, B
AU  - Marcom, PK
TI  - Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
J2  - N Engl J Med
PY  - 2015
VL  - 372
SP  - 134
EP  - 141
UR  - https://doi.org/10.1056/NEJMoa1406281
ER  - 
TY  - JOUR
LB  - 121.
AU  - Tolaney, SM
AU  - Guo, H
AU  - Pernas, S
AU  - Barry, WT
AU  - Dillon, DA
AU  - Ritterhouse, L
TI  - Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer
J2  - J Clin Oncol
PY  - 2019
VL  - 37
SP  - 1868
EP  - 1875
UR  - https://doi.org/10.1200/JCO.19.00066
ER  - 
TY  - JOUR
LB  - 122.
AU  - Jones, SE
AU  - Collea, R
AU  - Paul, D
AU  - Sedlacek, S
AU  - Favret, AM
AU  - Gore, I
TI  - Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study
J2  - Lancet Oncol
PY  - 2013
VL  - 14
SP  - 1121
EP  - 1128
UR  - https://doi.org/10.1016/S1470-2045(13)70384-X
ER  - 
TY  - JOUR
LB  - 123.
AU  - Baselga, J
AU  - Norton, L
AU  - Masui, H
AU  - Pandiella, A
AU  - Coplan, K
AU  - Miller, WH
AU  - Mendelsohn, J
TI  - Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
J2  - J Natl Cancer Inst
PY  - 1993
VL  - 85
SP  - 1327
EP  - 1333
UR  - https://doi.org/10.1093/jnci/85.16.1327
ER  - 
TY  - JOUR
LB  - 124.
AU  - Momparler, RL
AU  - Karon, M
AU  - Siegel, SE
AU  - Avila, F
TI  - Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells
J2  - Cancer Res
PY  - 1976
VL  - 36
SP  - 2891
EP  - 2895
ER  - 
TY  - JOUR
LB  - 125.
AU  - Pommier, Y
AU  - Leo, E
AU  - Zhang, H
AU  - Marchand, C
TI  - DNA topoisomerases and their poisoning by anticancer and antibacterial drugs
J2  - Chem Biol
PY  - 2010
VL  - 17
SP  - 421
EP  - 433
UR  - https://doi.org/10.1016/j.chembiol.2010.04.012
ER  - 
TY  - JOUR
LB  - 126.
AU  - Pang, B
AU  - Qiao, X
AU  - Janssen, L
AU  - Velds, A
AU  - Groothuis, T
AU  - Kerkhoven, R
TI  - Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin
J2  - Nat Commun
PY  - 2013
VL  - 4
SP  - 1908
UR  - https://doi.org/10.1038/ncomms2921
ER  - 
TY  - JOUR
LB  - 127.
AU  - Pang, B
AU  - de Jong, J
AU  - Qiao, X
AU  - Wessels, LF
AU  - Neefjes, J
TI  - Chemical profiling of the genome with anti-cancer drugs defines target specificities
J2  - Nat Chem Biol
PY  - 2015
VL  - 11
SP  - 472
EP  - 480
UR  - https://doi.org/10.1038/nchembio.1811
ER  - 
TY  - JOUR
LB  - 128.
AU  - Zitvogel, L
AU  - Kepp, O
AU  - Kroemer, G
TI  - Immune parameters affecting the efficacy of chemotherapeutic regimens
J2  - Nat Rev Clin Oncol
PY  - 2011
VL  - 8
SP  - 151
EP  - 160
UR  - https://doi.org/10.1038/nrclinonc.2010.223
ER  - 
TY  - JOUR
LB  - 129.
AU  - Andre, F
AU  - Dieci, MV
AU  - Dubsky, P
AU  - Sotiriou, C
AU  - Curigliano, G
AU  - Denkert, C
AU  - Loi, S
TI  - Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer
J2  - Clin Cancer Res
PY  - 2013
VL  - 19
SP  - 28
EP  - 33
UR  - https://doi.org/10.1158/1078-0432.CCR-11-2701
ER  - 
TY  - JOUR
LB  - 130.
AU  - Kroemer, G
AU  - Senovilla, L
AU  - Galluzzi, L
AU  - André, F
AU  - Zitvogel, L
TI  - Natural and therapy-induced immunosurveillance in breast cancer
J2  - Nat Med
PY  - 2015
VL  - 21
SP  - 1128
EP  - 1138
UR  - https://doi.org/10.1038/nm.3944
ER  - 
TY  - JOUR
LB  - 131.
AU  - Sistigu, A
AU  - Yamazaki, T
AU  - Vacchelli, E
AU  - Chaba, K
AU  - Enot, DP
AU  - Adam, J
TI  - Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
J2  - Nat Med
PY  - 2014
VL  - 20
SP  - 1301
EP  - 1309
UR  - https://doi.org/10.1038/nm.3708
ER  - 
TY  - JOUR
LB  - 132.
AU  - Parkes, EE
AU  - Walker, SM
AU  - Taggart, LE
AU  - McCabe, N
AU  - Knight, LA
AU  - Wilkinson, R
TI  - Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer
J2  - J Natl Cancer Inst
PY  - 2017
VL  - 109
UR  - https://doi.org/10.1093/jnci/djw199
ER  - 
TY  - JOUR
LB  - 133.
AU  - Ali, HR
AU  - Provenzano, E
AU  - Dawson, SJ
AU  - Blows, FM
AU  - Liu, B
AU  - Shah, M
TI  - Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients
J2  - Ann Oncol
PY  - 2014
VL  - 25
SP  - 1536
EP  - 1543
UR  - https://doi.org/10.1093/annonc/mdu191
ER  - 
TY  - JOUR
LB  - 134.
AU  - Denkert, C
AU  - von Minckwitz, G
AU  - Darb-Esfahani, S
AU  - Lederer, B
AU  - Heppner, BI
AU  - Weber, KE
TI  - Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
J2  - Lancet Oncol
PY  - 2018
VL  - 19
SP  - 40
EP  - 50
UR  - https://doi.org/10.1016/S1470-2045(17)30904-X
ER  - 
TY  - JOUR
LB  - 135.
AU  - Luen, SJ
AU  - Salgado, R
AU  - Fox, S
AU  - Savas, P
AU  - Eng-Wong, J
AU  - Clark, E
TI  - Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
J2  - Lancet Oncol
PY  - 2017
VL  - 18
SP  - 52
EP  - 62
UR  - https://doi.org/10.1016/S1470-2045(16)30631-3
ER  - 
TY  - JOUR
LB  - 136.
AU  - Dieci, MV
AU  - Conte, P
AU  - Bisagni, G
AU  - Brandes, AA
AU  - Frassoldati, A
AU  - Cavanna, L
TI  - Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
J2  - Ann Oncol
PY  - 2019
VL  - 30
SP  - 418
EP  - 423
UR  - https://doi.org/10.1093/annonc/mdz007
ER  - 
TY  - JOUR
LB  - 137.
AU  - Altman, DG
TI  - Clinical trials: subgroup analyses in randomized trials – more rigour needed
J2  - Nat Rev Clin Oncol
PY  - 2015
VL  - 12
SP  - 506
EP  - 507
UR  - https://doi.org/10.1038/nrclinonc.2015.133
ER  - 
TY  - JOUR
LB  - 138.
AU  - Peto, R
TI  - Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care
J2  - Br J Cancer
PY  - 2011
VL  - 104
SP  - 1057
EP  - 1058
UR  - https://doi.org/10.1038/bjc.2011.79
ER  - 
TY  - JOUR
LB  - 139.
AU  - Sun, X
AU  - Briel, M
AU  - Busse, JW
AU  - You, JJ
AU  - Akl, EA
AU  - Mejza, F
TI  - Credibility of claims of subgroup effects in randomised controlled trials: systematic review
J2  - BMJ
PY  - 2012
VL  - 344
SP  - e1553
UR  - https://doi.org/10.1136/bmj.e1553
ER  - 
TY  - JOUR
LB  - 140.
AU  - Sun, X
AU  - Ioannidis, JP
AU  - Agoritsas, T
AU  - Alba, AC
AU  - Guyatt, G
TI  - How to use a subgroup analysis: users’ guide to the medical literature
J2  - JAMA
PY  - 2014
VL  - 311
SP  - 405
EP  - 411
UR  - https://doi.org/10.1001/jama.2013.285063
ER  - 
TY  - JOUR
LB  - 141.
AU  - von Minckwitz, G
AU  - Procter, M
AU  - de Azambuja, E
AU  - Zardavas, D
AU  - Benyunes, M
AU  - Viale, G
TI  - Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
J2  - N Engl J Med
PY  - 2017
VL  - 377
SP  - 122
EP  - 131
UR  - https://doi.org/10.1056/NEJMoa1703643
ER  - 
TY  - JOUR
LB  - 142.
AU  - Chan, A
AU  - Delaloge, S
AU  - Holmes, FA
AU  - Moy, B
AU  - Iwata, H
AU  - Harvey, VJ
TI  - Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
J2  - Lancet Oncol
PY  - 2016
VL  - 17
SP  - 367
EP  - 377
UR  - https://doi.org/10.1016/S1470-2045(15)00551-3
ER  - 
TY  - JOUR
LB  - 143.
AU  - Martin, M
AU  - Holmes, FA
AU  - Ejlertsen, B
AU  - Delaloge, S
AU  - Moy, B
AU  - Iwata, H
TI  - Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
J2  - Lancet Oncol
PY  - 2017
VL  - 18
SP  - 1688
EP  - 1700
UR  - https://doi.org/10.1016/S1470-2045(17)30717-9
ER  - 
TY  - JOUR
LB  - 144.
AU  - Gianni, L
AU  - Pienkowski, T
AU  - Im, YH
AU  - Roman, L
AU  - Tseng, LM
AU  - Liu, MC
TI  - Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
J2  - Lancet Oncol
PY  - 2012
VL  - 13
SP  - 25
EP  - 32
UR  - https://doi.org/10.1016/S1470-2045(11)70336-9
ER  - 
TY  - JOUR
LB  - 145.
AU  - Gianni, L
AU  - Pienkowski, T
AU  - Im, YH
AU  - Tseng, LM
AU  - Liu, MC
AU  - Lluch, A
TI  - 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
J2  - Lancet Oncol
PY  - 2016
VL  - 17
SP  - 791
EP  - 800
UR  - https://doi.org/10.1016/S1470-2045(16)00163-7
ER  - 
TY  - JOUR
LB  - 146.
AU  - Howie, LJ
AU  - Scher, NS
AU  - Amiri-Kordestani, L
AU  - Zhang, L
AU  - King-Kallimanis, BL
AU  - Choudhry, Y
TI  - FDA approval summary: pertuzumab for adjuvant treatment of HER2-positive early breast cancer
J2  - Clin Cancer Res
PY  - 2019
VL  - 25
SP  - 2949
EP  - 2955
UR  - https://doi.org/10.1158/1078-0432.CCR-18-3003
ER  - 
TY  - GEN
LB  - 147.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Pertuzumab for Adjuvant Treatment of HER2-positive Early Stage Breast Cancer
CY  - London
PB  - NICE
PY  - 2019
UR  - www.nice.org.uk/guidance/ta569
Y2  - 3 July 2020
ER  - 
TY  - ELEC
LB  - 148.
AU  - National Institute for Health and Care Excellence
TI  - Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
UR  - www.nice.org.uk/guidance/ta612
M1  - 15 July 2020
ER  - 
TY  - JOUR
LB  - 149.
AU  - Esserman, LJ
AU  - DeMichele, A
TI  - Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change?
J2  - Clin Cancer Res
PY  - 2014
VL  - 20
SP  - 3632
EP  - 3636
UR  - https://doi.org/10.1158/1078-0432.CCR-13-3131
ER  - 
TY  - GEN
LB  - 150.
AU  - European Medicines Agency
TI  - Perjeta
CY  - Amsterdam
PB  - EMA
UR  - www.ema.europa.eu/en/medicines/human/EPAR/perjeta#authorisation-details-section
ER  - 
TY  - GEN
LB  - 151.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Pertuzumab for the Neoadjuvant Treatment of HER2-positive Breast Cancer.
CY  - London
PB  - NICE
PY  - 2016
UR  - www.nice.org.uk/guidance/ta424
Y2  - 3 July 2020
ER  - 
TY  - JOUR
LB  - 152.
AU  - von Minckwitz, G
AU  - Huang, CS
AU  - Mano, MS
AU  - Loibl, S
AU  - Mamounas, EP
AU  - Untch, M
TI  - Trastuzumab emtansine for residual invasive HER2-positive breast cancer
J2  - N Engl J Med
PY  - 2019
VL  - 380
SP  - 617
EP  - 628
UR  - https://doi.org/10.1056/NEJMoa1814017
ER  - 
TY  - JOUR
LB  - 153.
AU  - Piccart, MJ
TI  - Why your preferred targeted drugs may become unaffordable
J2  - Cancer Res
PY  - 2013
VL  - 73
SP  - 5849
EP  - 5851
UR  - https://doi.org/10.1158/0008-5472.CAN-13-1486
ER  - 
TY  - JOUR
LB  - 154.
AU  - Bray, F
AU  - Ferlay, J
AU  - Soerjomataram, I
AU  - Siegel, RL
AU  - Torre, LA
AU  - Jemal, A
TI  - Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
J2  - CA Cancer J Clin
PY  - 2018
VL  - 68
SP  - 394
EP  - 424
UR  - https://doi.org/10.3322/caac.21492
ER  - 
TY  - GEN
LB  - 155.
AU  - World Health Organization
TI  - WHO Model List of Essential Medicines [11/2015]
CY  - Geneva
PB  - WHO
PY  - 2015
UR  - www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1
Y2  - 3 July 2020
ER  - 
TY  - ELEC
LB  - 156.
AU  - Daily Nation
TI  - WHO Updates List of Essential Drugs
UR  - www.nation.co.ke/kenya/healthy-nation/who-updates-list-of-essential-drugs-409508
ER  - 
TY  - JOUR
LB  - 157.
AU  - Coory, M
AU  - Thornton, K
TI  - Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review
J2  - Breast Cancer Res Treat
PY  - 2019
VL  - 176
SP  - 17
EP  - 25
UR  - https://doi.org/10.1007/s10549-019-05227-7
ER  - 
TY  - BOOK
LB  - 158.
AU  - Curtis, L
AU  - Burns, A
TI  - Unit Costs of Health and Social Care 2017
CY  - Canterbury
PB  - Personal Social Services Research Unit, University of Kent
PY  - 2017
ER  - 
TY  - JOUR
LB  - 159.
AU  - Marcheselli, R
AU  - Marcheselli, L
AU  - Cortesi, L
AU  - Bari, A
AU  - Cirilli, C
AU  - Pozzi, S
TI  - Risk of second primary malignancy in breast cancer survivors: a nested population-based case-control study
J2  - J Breast Cancer
PY  - 2015
VL  - 18
SP  - 378
EP  - 385
UR  - https://doi.org/10.4048/jbc.2015.18.4.378
ER  - 
TY  - ELEC
LB  - 160.
AU  - Cancer Research UK
TI  - Cancer Incidence by Age
UR  - www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/age#heading-Zero
M1  - 1 November 2019
ER  - 
TY  - GEN
LB  - 161.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Ribociclib with an Aromatase Inhibitor for Previously Untreated, Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
IS  - Technology appraisal guidance [TA496]
CY  - London
PB  - NICE
PY  - 2017
UR  - www.nice.org.uk/guidance/ta496
Y2  - 3 July 2020
ER  -